response to esmolol/esmolol withdrawal may predict effective therapy.
Methods and Results Thirty-six patients with unexplained recurrent syncope/presyncope (7 to 35 years old, known heart disease or arrhythmia in 14) underwent 2 to 4 HUT tests (600, 49 minutes): (1) baseline, (2) esmolol (500 ug/kg plus 50 ,ug kg`. min'1), (3) esmolol withdrawal (HUT continued after esmolol stopped), and (4) isoproterenol if tests 1 through 3 were negative and isoproterenol was not contraindicated. A positive test reproduced symptoms with hypotension or bradycardia, requiring recumbency for recovery. Twenty-five had positive tests, and 11 had negative tests. In 5, only the baseline ead-upright tilt testing (HUT) is valuable for H evaluation of unexplained syncope in adults'-10 and in childrenl"17; however, the efficacy of HUT alone in reproducing syncope is relatively low.2 '18 Because isoproterenol can provoke syncope resembling vagal syncope, isoproterenol is often added during HUT as an exogenous catecholamine stimulus of syncope to increase sensitivity of HUT.2, 18, 19 The mechanism of this effect may be that isoproterenol increases cardiac contractility, leading to stimulation of a class of unmyelinated cardiac vagal afferents responsive to mechanical stimulation (distinct from the phenyl diguanide-sensitive [chemosensitive] class of afferents). Through the vagus and possibly through spinally projecting neurons of the nucleus raphe pallidus of the medulla, this leads to a vagal efferent and possibly a sympathoinhibitory response with hypotension and bradycardia and syncope similar or identical to clinical syncope. [20] [21] [22] Indeed, the mechanism of syncope may be virtually identical to that of some clinical syncope, eg, where either mechanosensitive or chemosensitive23,24 vagal afferents are activated in aortic stenosis or in inferior wall ischemia.
Although isoproterenol may be effective in provoking syncope in HUT protocols, addition of isoproterenol is not without disadvantages. Isoproterenol is contraindicated or hazardous in many patients with heart disease because of its arrhythmogenic and 3-adrenergic prop- erties, which may cause hemodynamic decompensation in patients with tachycardias, severe hemodynamic lesions (eg, obstruction), or ischemic heart disease. Be (1) that as a form of P-adrenergic stimulation, acute withdrawal of esmolol during HUT has fewer side effects and disadvantages (including false-positives) than isoproterenol, and (2) that the response to acute testing with a p-blocker and during ,-blocker withdrawal will facilitate clinical management.
Methods

Patient Selection and Evaluation
The patient population consisted of consecutive individuals with unexplained recurrent syncope or presyncope who underwent HUT. All were evaluated by history and physical examination. Individuals with isolated upright syncope triggered by surprise or fright, resolving promptly on recumbency, were excluded. (Vasovagal syncope was diagnosed presumptively in such patients on clinical grounds if there was no evidence of structural heart disease or arrhythmia by clinical evaluation, two-dimensional echocardiography, and Holter monitoring.)
Evaluation included physical examination with blood pressure measurement with the patient supine, sitting, and standing; 12-lead ECG; two-dimensional echocardiography, and 24-to 48-hour Holter monitoring as indicated. An exercise test using the Bruce protocol was completed by those who had symptoms with exercise.
HUT was recommended as a diagnostic test before consideration of catheterization, electrophysiological testing, or treatment in patients in whom historic features were atypical or idiosyncratic for simple fainting and clinical evaluation was not diagnostic.
Tilt Testing
Patients underwent two to four head-upright (60°) tilt tests lasting up to 49 minutes each, including (1) baseline tilt, (2) esmolol tilt (after esmolol 500 j,g/kg intravenously over 2 to 5 minutes, followed by 50 ,ug* kg-l -min-1 intravenous infusion), (3) esmolol withdrawal tilt (tilt continued after esmolol stopped), and (4) isoproterenol tilt if tests 1 through 3 were negative and there were no contraindications to isoproterenol (eg, possible significant hemodynamic lesion, supraventricular or ventricular tachycardia, ischemia, or severe hypertension). Between tests, the patients rested supine for 20 to 60 minutes. See Table 1 .
Testing was started at midday 30 to 60 minutes after placement of an intravenous cannula. Noninvasive continuous ECG and blood pressure monitoring were used (Quinton Q-5000, Colin Pulsemate BX-5). Studies were performed in a darkened room with no threatening equipment visible to the patient after 20 to 60 minutes of rest in the supine position. A motorized tilt table with foot-plate support was used. Transit time from 00 to 600 was 23 seconds.
Baseline tilt was maintained for 49 minutes or until syncope or intolerable symptoms developed, at which time the patient was returned to the supine position, and noxious stimulation was initiated to determine the moment of recovery of consciousness. After this 49-minute baseline tilt test, the esmolol protocol was initiated.
The esmolol tilt test was performed after supine rest for 20 to 30 minutes. Esmolol (Brevibloc) was administered intravenously with a 500-,ug/kg loading dose over 2 to 5 minutes followed by continuous infusion at a rate of 50 ,ugg* kg`-min-l. The The isoproterenol tilt test was performed if the three previous tests were negative and there were no contraindications to isoproterenol. At the point of at least 5 half-lives free of esmolol (esmolol mean half-life, =4 to 9 minutes in different age groups), isoproterenol was given at 0.01 ug* kg`. min-1, titrated upward every 1 to 2 minutes to target heart rate .120% of baseline. The 600 head-up tilt then was initiated. Infusion was reduced for heart rate > 150 beats per minute. Tilt was continued 15 minutes or until syncope or intolerable symptoms occurred.
Responses to HUT
A positive test reproduced symptoms in association with hypotension or bradycardia and required recumbency for recovery. If the patient had transient symptoms that did not require recumbency for recovery, HUT was continued, and this was considered a transient positive response. Syncope was considered to be false-positive if severe hypertension preceded and provoked the vagal reaction, indicating that this represented a normal arterial baroreceptor reflex. If a patient required cardiopulmonary resuscitation or transcutaneous pacing for resolution of symptoms, the patient was considered positive for that HUT, but the protocol was aborted.
There are seven possible patterns of test results: (1) all negative tests, (2) positive baseline but all negative provocative tests, (3) negative or (4) positive baseline and positive esmolol tilt, (5) negative or (6) positive baseline tilt and negative esmolol but positive esmolol withdrawal tilt, and (7) first three tilt tests were negative but with a positive isoproterenol tilt.
These responses to provocation predict j3-blocker-responsive syncope in groups 5, 6 , and 7 and f3-blocker-nonresponsive syncope in groups 3 and 4.
Medications were or were not given after discussion with the patient and the patient's parents and at the discretion of the study physicians. Follow-up every 3 to 6 months was scheduled.
Data Analysis
For each of the four different tilt groups, systolic and diastolic blood pressures, heart rate, respiratory rate, and heart rate were recorded for the immediate pretilt, immediate posttilt, immediate presymptomatic period, and symptomatic period when the test was terminated, as well as for every 30 to 60 seconds during the tilt before symptoms and termination. Fisher one-factor ANOVA was used to compare the following variables among the several groups: initial heart rate and systolic blood pressure; initial change (increment or decrement) in heart rate; systolic and diastolic blood pressures upon tilt; maximal heart rate during tilt; maximal increment of heart rate during tilt; and maximal systolic blood pressure during tilt. Student-Newman-Keuls q test (SNK) was used for comparisons between groups. The Fisher exact test was used for analysis of 2x2 contingency tables.
Results
Patient Population
The study population included 36 patients with unexplained recurrent syncope or presyncope despite standard workup. The patients ranged in age from 7 Table 4 .
In 23 patients the baseline, esmolol, or esmolol withdrawal tests were positive. In 2 patients, the isoproterenol test was positive but all the other tilt tests were negative.
Of the patients with at least one positive test, 5 had positive baseline tilt, 15 had positive baseline and positive esmolol or esmolol withdrawal tilt, 3 had negative baseline but positive esmolol or esmolol withdrawal tilt, and 2 had positive isoproterenol but negative baseline, esmolol, and esmolol withdrawal tilts.
The positive baseline tests became positive at less than 10 minutes in 5 of 20 patients only. In the specific group of 7 patients positive both at baseline and on esmolol withdrawal, 6 became positive during the baseline tilt only after 10 minutes.
In patients with any positive test, the precipitating cause of syncope was a depression of blood pressure with preserved (or elevated) heart rate in 19 and depression of heart rate or asystole in 6 .
No patient had a positive test only during esmolol HUT (ie, negative baseline but positive esmolol). Such a pattern would be expected in false-positives as a result of a ,8-blocker.
A typical vagal response to esmolol withdrawal is shown in Fig 2. Tilt occurred at time t=0 and esmolol withdrawal shortly after t=30 minutes. After esmolol withdrawal, the heart rate increased. At 45 minutes, hypotension (71 mm Hg) was observed with symptoms of lightheadedness. The child required recumbency for recovery (48 to 49 minutes).
One isoproterenol positive was one of two tests that were falsely positive for vasovagal syncope because of transient hypertension (blood pressure, 180/120) precipitating a normal arterial baroreceptor reflex with hypotension.
Results suggested that 17 patients had syncope responsive to 13-blocker, and 8 patients were unresponsive. Fifteen patients were subjectively improved with 9-month median follow-up (range, 4 to 21 months), 4 were worse, and 6 are lost to follow-up. There was no preponderance of any particular test result type in patients whose symptoms were worse. Except for positive isoproterenol tilt test responses, there was no particular hemodynamic response to tilt that failed to predict response to treatment.
Of 2 patients positive on isoproterenol and negative on all other tests, one was a false-positive previously mentioned; the other became worse (with increased presyncope) when given a 1-blocker. Thus, both positive isoproterenol tilt tests appear to represent false-positives. Of course, these isoproterenol tilt tests were performed after baseline, esmolol, and esmolol withdrawal tilt tests were all negative, in accordance with protocol. In this context, isoproterenol tilt test positive response does not appear predictive of 13-blocker-responsive syncope.
Esmolol and esmolol withdrawal accurately predicted therapeutic response in 15 patients, and isoproterenol predicted therapeutic response in none. For the 11 patients with all negative tests, no further recurrences of syncope occurred. Complications One patient had severe presyncope in the first half hour after completion of the test; the symptoms resolved promptly with recumbency. The only noteworthy complications of the study were episodes of hypertension in 4 patients (caused by isoproterenol in 2). The 2 patients falsely positive for syncope (provoked in both by isoproterenol) recovered without complications.
Discussion
The most important finding of this study is that esmolol withdrawal appears to be an effective or superior alternative to isoproterenol in head-upright tilt testing.
Esmolol Withdrawal
Esmolol withdrawal (acute withdrawal of esmolol during HUT) is a form of f-adrenergic stress involving endogenous catecholamines at physiological levels rather than exogenous catecholamines at pharmacological doses. Esmolol withdrawal during tilt provokes syncope by unmasking the endogenous epinephrine and norepinephrine elicited by HUT. These catecholamines then provoke syncope presumably by increasing cardiac contractility and thereby stimulating mechanosensitive vagal afferents, which reflexly lead to hypotension and bradycardia in a manner similar to that postulated for isoproterenol (and some spontaneous syncope).
Although The physiological effects of esmolol withdrawal are similar to isoproterenol, with important exceptions. Although the maximal heart rate is elevated with both isoproterenol and esmolol withdrawal, this increase is due to an increased supine heart rate in isoproterenol testing (caused by the /3-adrenergic effects of isoproterenol while the patient is supine), but in esmolol withdrawal testing, the maximal heart rate change (supine to tilt) is increased. This suggests that esmolol withdrawal specifically augments the stress associated with HUT by unmasking the endogenous catecholamines epinephrine and norepinephrine released in response to tilt. Isoproterenol does not augment the stress of tilt, rather it adds a f3-adrenergic stress independent of HUT. This effect is reflected in increased heart rate and systolic blood pressure in the supine position observed with isoproterenol, making isoproterenol tilt a poor model for spontaneous syncope and near syncope (which do not occur in the supine position). These findings further reflect the excessive (nonphysiological) /3-adrenergic stress associated with use of the exogenous /3-adrenergic agent isoproterenol at pharmacological doses rather than the endogenous catecholamines at physiological levels with esmolol withdrawal. Indeed, with isoproterenol, systolic hypertension was documented in two instances, with a falsepositive syncope caused by a normal arterial baroreceptor reflex in one of these patients. Neither of these effects were observed with esmolol withdrawal. (It may not be surprising that the arterial baroreceptor reflex is a source of false-positive syncope in HUT: Experimental feline work of Oberg and Thoren30 has previously shown that excitation of the arterial baroreceptor causes relatively greater depressor effect than stimulation of afferent cardiac vagal fibers.)
Esmolol testing with esmolol withdrawal during tilt may provide useful information on ,-blocker responsiveness. Furthermore, no false-positive attributable to esmolol was found (ie, an instance where esmolol tilt was the only positive tilt), and no false-positives were attributed to esmolol withdrawal. However, one or both of the two isoproterenol positives were false-positives. This result supports the possibility that esmolol withdrawal may be more specific than isoproterenol in detecting mechanisms of spontaneous outpatient syncope. Isoproterenol appears to add negligible sensitivity to esmolol withdrawal testing, although it adds risks and disadvantages.
Safety of Esmolol and Esmolol Withdrawal
The esmolol and esmolol withdrawal protocols appear to be safe for evaluation of unexplained syncope, even in a group of patients with no exclusion criteria based on heart disease, arrhythmia, or conduction system disease. The safety of esmolol and esmolol withdrawal protocols is emphasized by the fact that these were used safely even in two children in whom later catheterization uncovered severe conduit obstruction with systemic right ventricular pressure in one and severe obstruction with provocation in a case of hypertrophic cardiomyopathy in the other. Both children had appeared on repeated pretilt echocardiograms not to have significant hemodynamic derangements, the first because of a significant underestimate of conduit gradient that was due either to suboptimal acoustic window or to long segment stenosis, the latter because of minimal resting gradient. The fact that this protocol was safely used in these and other patients with history of significant heart disease supports further investigation of esmolol with esmolol withdrawal testing during HUT as a first-line diagnostic investigation before invasive testing for patients with or without heart disease. The esmolol and esmolol withdrawal protocols thus may have broader applicability than isoproterenol HUT 
